Theriva VIRAGE Phase 2b: VCN-01+GA OS 10.8mo (HR0.57, p=0.055), PFS 7.0mo (HR0.55, p=0.011)

Theriva Biologics, Inc.

In FAS population, VCN-01 + GA improved median OS to 10.8 mo vs 8.6 mo (HR 0.57, p=0.055) and PFS to 7.0 vs 4.6 mo (HR 0.55, p=0.011).
Patients receiving 2 VCN-01 doses starting GA cycle 4 had OS 14.8 vs 11.6 mo (HR 0.44, p=0.046) and PFS 11.2 vs 7.4 mo (HR 0.48, p=0.017).
VCN-01 well tolerated; all 13 related serious adverse events resolved; common: flu-like symptoms (13.2%), transaminase increase (5.7%).
Data to be presented at ESMO 2025 mini oral session on Oct 20; abstract published. Study met primary endpoints.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.